Electromed, Inc. Form 10-Q Summary
Reporting period: Three months ended September 30, 2023. Although identified as “2023 Q1” in the request, the filing treats this period as the first quarter of fiscal 2024. Results are unaudited and should be read with the fiscal 2023 Form 10-K.
Business Context
Electromed develops, manufactures and markets SmartVest airway-clearance systems using High Frequency Chest Wall Oscillation technology. Products are sold through homecare, homecare distributor, hospital and international channels. The SmartVest Clearway received FDA 510(k) clearance in December 2022 and had been launched in the homecare market.
Key Financial Metrics
| Metric | Q1 FY2024 | Q1 FY2023 | Change |
|---|---|---|---|
| Net revenue | $12.324 million | $10.658 million | 15.6% increase |
| Gross profit | $9.498 million | $8.331 million | 14.0% increase |
| Gross margin | 77.1% | 78.2% | Down 110 basis points |
| Operating income | $142,000 | $44,000 | Increase of $98,000 |
| Net income | $155,000 | $81,000 | Increase of $74,000 |
| Diluted EPS | $0.02 | $0.01 | Increase |
| Net cash used in operating activities | $244,000 | $1.694 million | Improved by $1.450 million |
Homecare revenue increased 15.8% to $11.153 million, primarily from higher referrals, approvals and reimbursement rates. Hospital revenue increased 29.7% to $507,000, while homecare distributor revenue increased 3.4% to $573,000 and international revenue increased 12.3% to $91,000.
SG&A increased 14.5% to $9.150 million, including an 18.1% increase in payroll and compensation-related costs and a 108.3% increase in discretionary marketing expenses. R&D declined 30.9% to $206,000 as Clearway development costs decreased following launch. Net interest income rose to $77,000 due to higher savings rates.
At September 30, 2023, cash and cash equivalents were $7.024 million, compared with $7.372 million at June 30, 2023. Working capital was $30.419 million. Accounts receivable were $23.455 million, contract assets were $544,000 and inventories were $4.480 million. Total liabilities were $5.844 million and shareholders’ equity was $38.222 million.
Investing cash outflows were $133,000, consisting of $109,000 for property and equipment and $24,000 for intangible assets. Financing cash inflows were $29,000 from stock-option exercises. The company reported no outstanding borrowings.
Material Changes Versus the Prior Comparable Period
- Revenue growth was driven mainly by homecare activity, supported by additional direct sales representatives and reimbursement personnel.
- Gross margin contracted because of higher material and labor costs.
- Operating profitability and net income improved, but profitability remained modest relative to revenue.
- Operating cash use narrowed substantially, although cash flow remained negative because of annual incentive payments and reductions in accrued liabilities.
- Share-based compensation increased to $371,000 from $95,000, including $73,000 related to performance-based restricted stock units granted to the CEO.
- The company issued 255,562 stock options during the quarter and had 697,552 options outstanding at September 30, 2023.
- No common stock repurchases occurred during the quarter. Approximately $275,000 remained available under the repurchase authorization.
Guidance, Outlook, Risks and Unusual Items
Management did not provide specific numerical revenue or earnings guidance. Management stated that current working capital, cash flows and available borrowings are expected to support anticipated needs for the next twelve months and that cash resources are expected to support fiscal 2024 and the foreseeable future.
The company’s $2.5 million revolving credit facility had no outstanding balance and was fully available at September 30, 2023. The facility was scheduled to expire on December 18, 2023 if not renewed, and is subject to financial and nonfinancial covenants, including a minimum tangible net worth of $10.125 million. Borrowings bear interest at the prime rate less 1.00% and are secured by substantially all tangible and intangible assets.
Key risks include reimbursement reductions or denials from Medicare, Medicaid and commercial payers; expiration of applicable reimbursement waivers; component shortages and inflation; regulatory or reimbursement changes; competition; execution risks from salesforce expansion; cybersecurity threats; product or technical issues; international regulation; intellectual property protection; and failure to renew or replace the credit facility.
A previously disclosed data-breach class action settlement received final court approval in July 2023. The company paid $825,000 into the settlement fund during the quarter; the amount was covered by insurance and reduced other current assets and accrued liabilities.
The company adopted the expected-credit-loss accounting standard effective July 1, 2023; adoption did not have a material impact. Management reported no material changes in critical accounting estimates, and disclosure controls and procedures were effective as of September 30, 2023.
Important Facts for Investors to Verify
- Whether the credit facility was renewed beyond its December 18, 2023 expiration date and on what terms.
- Whether reimbursement rates, approval trends and payer mix continue to support homecare revenue growth.
- Whether higher material, labor, salesforce and marketing costs pressure gross and operating margins.
- The collectability of the $23.455 million accounts receivable balance and the assumptions underlying $544,000 of contract assets.
- The adequacy of the $1.424 million warranty reserve and the $360,000 inventory-obsolescence reserve.
- The future cash impact of share-based compensation, including $1.079 million of unrecognized PSU expense and other unrecognized award expense.
- Any further legal, cybersecurity or data-breach-related costs beyond the insured settlement payment.